Sitagliptin induced acute severe nasopharyngitis

V. Krishnan, Shivali Rai


Acute nasopharyngitis is one of the distressing adverse effects seen with the use of dipeptidyl peptidase-4 inhibitors like sitagliptin. Here, we report a case of acute severe nasophryngitis with the use of sitagliptin for diabetes mellitus.


Sitagliptin, Adverse effects, Nasopharyngitis

Full Text:



Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004;36:867-76. [DOI via Crossref]

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68.

Landis BN, Grouzmann E, Monod M, Busso N, Petak F, Spiliopoulos A, et al. Implication of dipeptidylpeptidase IV activity in human bronchial inflammation and in bronchoconstriction evaluated in anesthetized rabbits. Respiration. 2008;75:89-97. [DOI via Crossref] [DOI via Crossref]

Costa DJ, Bousquet PJ, Ryan D, Price D, Demoly P, Brozek J, et al. Guidelines for allergic rhinitis need to be used in primary care. Prim Care Resp J. 2009;18(4):250-7. [DOI via Crossref] [DOI via Crossref]

Adler AI, Shaw EJ, Stokes T, Ruiz F. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ. 2009;338:1328-9. [DOI via Crossref] [DOI via Crossref]

Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007;120:403-8. [DOI via Crossref] [DOI via Crossref]

Grouzmann E, Monod M, Landis B, Wilk S, Brakch N, Nicoucar K, et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J. 2002;16:1132-4.